CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


LeflunomideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2049 Recombinase aided amplification (RAA) assay Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19

This study aims to examine the tolerability of high dose of leflunomide in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications.

NCT04361214 COVID-19 Drug: Leflunomide

Primary Outcomes

Description: Number of subjects requiring leflunomide dose modifications

Measure: Tolerability of high dose leflunomide as measured by leflunomide dose modifications

Time: 14 days

Description: Number of subjects that discontinue leflunomide

Measure: Tolerability of high dose leflunomide as measured by discontinuation of leflunomide

Time: 14 days

Description: Number of Adverse Events observed in all subjects for the duration of the study

Measure: Tolerability of high dose leflunomide as measured by Adverse Events

Time: 14 days

Secondary Outcomes

Description: Number of patients admitted to hospital during study period

Measure: Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized

Time: 14 days

Description: The number of days to reach first fever normalization (criteria for normalization: temperature < 100.4 F)

Measure: Time to defervescence as measured in days while on treatment protocol

Time: 14 days

Description: Number of days to resolve other symptoms, as assessed by a standardized questionnaire for symptom assessment

Measure: Resolution of other COVID-19 symptoms measured in days while on treatment protocol

Time: 14 days


No related HPO nodes (Using clinical trials)